Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Dec;20(12):8673-8683.
doi: 10.1002/alz.14314. Epub 2024 Oct 22.

Assessing clinical progression measures in Alzheimer's disease trials: A systematic review and meta-analysis

Jonathan McLaughlin  1 , William J Scotton  2 , Natalie S Ryan  2   3 , John A Hardy  2   3 , Maryam Shoai  2   3
Affiliations
Meta-Analysis

Assessing clinical progression measures in Alzheimer's disease trials: A systematic review and meta-analysis

Jonathan McLaughlin et al. Alzheimers Dement. 2024 Dec.

Abstract

Introduction: Assessing treatments for Alzheimer's disease (AD) relies on reliable tools for measuring AD progression. In this analysis, we evaluate the sensitivity of clinical progression measures in AD within randomized controlled trials (RCTs) with confirmed positive amyloid (Aβ+) status prior to trial enrollment.

Methods: Excluding trials targeting non-cognitive symptoms, we conducted meta-analyses on progression measures from 25 selected RCTs using R version 4.2.0, along with the metafor and emmeans libraries.

Results: The Functional Activities Questionnaire (FAQ) demonstrated the greatest sensitivity over 12 weeks. Other cognitive measures demonstrated lower sensitivity. The integrated Alzheimer's Disease Rating Scale (iADRS) and Clinical Dementia Rating-Sum of Boxes (CDR-SB) seemed more effective than their individual cognitive components. Neuropsychiatric measures were the least sensitive in measuring progression.

Discussion: Functional measures generally outperformed other measure categories. Purely cognitive domain-based measures were suboptimal for tracking early AD progression. Ideally, future measures should incorporate both cognitive and functional components to enhance sensitivity.

Highlights: Concerns remain regarding the limitations of current outcome measures used in AD clinical trials, particularly their sensitivity in the early and preclinical stages of the disease, which hampers their reliability as indicators of AD progression. The Functional Activities Questionnaire (FAQ) demonstrated the most substantial weighted mean change over 12 weeks, followed by the Mini-Mental State Examination (MMSE). Functional measures outperformed other measure categories. Composite scores of integrated Alzheimer's Disease Rating Scale and Clinical Dementia Rating-Sum of Boxes are more sensitive to change than their individual cognitive components, possibly driven by the functional components of the score. Neuropsychiatric measures analyzed in this study appeared to be the least sensitive in measuring progression.

Keywords: Alzheimer's dementia; amyloid positive; meta‐analysis; outcome measures; progression measures; randomized controlled trials; systematic review.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest. Author disclosures are available in the Supporting information.

Figures

FIGURE 1
FIGURE 1
PRISMA flow diagram.
FIGURE 2
FIGURE 2
Forest plots of meta‐regression for functional, cognitive, composite, and neuropsychiatric measures from 25 RCTs. Each panel depicts one group of progression measures with their respective meta‐regression results displayed under the panel for clarity.
See this image and copyright information in PMC

References

    1. Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer's disease. N Engl J Med. 2021;384(18):1691‐1704. - PubMed
    1. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388(1):9‐21. - PubMed
    1. Harris E. Alzheimer Drug Lecanemab Gains Traditional FDA Approval. JAMA. 2023;330(6):495. - PubMed
    1. Swash M, Brooks DN, Day NE, Frith CD, Levy R, Warlow CP. Clinical trials in Alzheimer's disease. A report from the Medical Research Council Alzheimer's Disease Clinical Trials Committee. J Neurol Neurosurg Psychiatry. 1991;54(2):178‐181. - PMC - PubMed
    1. Mcghee DJM, Ritchie CW, Thompson PA, Wright DE, Zajicek JP, Counsell CE. A systematic review of biomarkers for disease progression in Alzheimer's disease. PLoS One. 2014;9(2):e88854. - PMC - PubMed

MeSH terms

LinkOut - more resources